查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014856

關節疼痛治療注射藥物市場：按分子類型、適應症、給藥途徑、患者年齡層和最終用戶分類－2026-2032年全球市場預測

Joint Pain Injections Market by Molecule Type, Indication, Route Of Administration, Patient Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年，用於治療關節疼痛的注射藥物市值為55.7億美元，預計到2026年將成長至61.6億美元，複合年成長率為11.38%，到2032年將達到118.5億美元。

主要市場統計數據
基準年 2025 55.7億美元
預計年份：2026年 61.6億美元
預測年份 2032 118.5億美元
複合年成長率 (%) 11.38%

為決策者提供的全面介紹，概述了將重塑全球關節痛注射生態系統的臨床、技術和商業性因素。

在現代整形外科、風濕病學和運動醫學中，注射療法在關節疼痛治療中扮演著核心角色，臨床醫生致力於尋找有效且靶向性強的治療方法，以緩解症狀並最大程度地減少恢復時間。過去十年間，臨床醫生一直在權衡傳統的皮質類固醇注射療法與日益豐富的生物製藥和關節內粘稠補充療法。同時，手術技巧和影像導引在治療結果中的重要性也日益凸顯。因此，臨床討論正從單一治療方法的模式轉向以安全性、可重複性和患者自述功能改善為優先考慮因素的綜合治療路徑。

本文詳細探討了加速關節疼痛注射療法廣泛應用並改變標準治療的技術、臨床和政策變化。

關節疼痛注射療法的臨床實踐和商業性格局正在經歷變革，這主要得益於生物製藥、影像技術和醫療保險報銷機制的進步。首先，臨床上對再生醫學方法的興趣日益濃厚，使得富血小板血漿（PRP）及相關自體療法從小眾選擇躍升為主流研究對象，迫使生產商改善處理試劑盒和品管。同時，透明質酸製劑的改進和皮質類固醇的持續應用依然具有治療意義，但其應用定位正根據患者特徵和關節特異性治療結果進行更精準的調整。

對 2025 年美國實施的關稅措施如何重塑關節痛注射療法的採購、定價動態和供應鏈策略進行嚴格分析。

美國於2025年實施的關稅調整的累積影響已波及關節痛注射產品及其組件的整個採購、定價和供應鏈決策過程。部分進口醫療用品關稅的提高增加了一次性注射盒、透明質酸原料和某些醫療設備組件的接收成本，促使企業立即與供應商進行談判並重新檢視籌資策略。為因應這一局面，跨國製造商加快了在地化生產的步伐，將高價值的組裝流程轉移到國內，或重新認證免稅地區的替代供應商，以緩解利潤率下降的局面。

將分子類型、臨床適應症、給藥途徑、醫療機構和患者年齡層與實際實施策略聯繫起來的詳細細分見解。

依分子類型分類，市場可分為成熟的皮質類固醇、各種玻尿酸製劑和富血小板血漿（PRP）療法，每種療法都具有其獨特的臨床和商業性意義。皮質類固醇包括倍Betamethasone、Methylprednisolone和丙酮化曲安奈德等特性明確的藥物，其效力、藥物儲存特性和症狀緩解持續時間的差異會影響臨床醫生的選擇。透明質酸製劑分為交聯型和線性型。交聯型旨在透過延長關節內停留時間來更長期地控制症狀，而線性型則優先考慮便利性、低黏度和可能更優的快速起效。富血小板血漿分為去除白血球型和含白血球型，這些生物特性的差異會影響發炎反應、監管和治療過程中的操作要求。

重點區域觀點，著重分析各大區域在報銷制度、法規、臨床實務模式及製造能力上的差異。

區域趨勢持續推動美洲、歐洲、中東和非洲以及亞太地區採取差異化策略，每個地區都展現出其獨特的法規環境、報銷框架和臨床實踐模式。在美洲，門診手術的擴張、門診手術中心的容量提升以及保險公司日益嚴格的審查正在影響著採購和臨床應用，促使製造商優先考慮能夠證明療效和手術效率的相對證據。從以醫院為中心轉變為分散式醫療環境的轉變也推動了對培訓計畫的投資，旨在使超音波引導下的子手術在不同的醫療服務提供者網路中標準化。

該報告揭示了企業層面的策略見解，闡述了夥伴關係、產品組合整合和證據產生如何為關節痛注射服務創造競爭優勢。

關節疼痛注射劑市場中各公司的競爭格局反映了它們在產品系列整合、服務拓展和通路最佳化方面的策略性舉措。老牌製藥公司持續最佳化其皮質類固醇和透明質酸產品線，同時選擇性地投資於利用專業生物製藥和醫療設備的給藥解決方案。同時，醫療設備和診斷設備製造商正與生物製藥創新者合作，透過提供包含注射劑、導引系統、治療包和臨床醫生培訓的捆綁式解決方案，提升其對醫療服務提供者和保險公司的價值提案。

為製藥公司、臨床醫生和支付者提供實用建議，以增強供應鏈韌性，驗證臨床價值，並加速在所有醫療保健機構中的應用。

行業領導者應優先考慮一系列切實可行的舉措，將洞察轉化為強勁的成長和臨床影響力。首先，透過供應商多元化、盡可能選擇國內製造合作夥伴以及維護清晰的海關和分類策略，投資於供應鏈韌性。這將有助於降低關稅衝擊和短期中斷帶來的風險。其次，應重點關注強調超音波引導給藥和標準化操作流程的臨床醫生培訓項目，因為操作的準確性直接影響患者對療效的感知以及支付方的接受度。

我們將以透明的方式解釋我們的混合研究途徑，該方法結合了對臨床醫生的訪談、供應商資訊、監管審查和專家檢驗，以得出可靠的研究結果。

本分析採用多方面研究方法，結合一手定性研究和檢驗的二手信息，以確保得出平衡檢驗可驗證的結論。一手研究包括對執業骨科醫生、風濕症醫師、介入放射科醫生和手術室護士進行詳細訪談，以及與重點地區的採購經理和監管專家進行結構化討論。此外，還舉辦了諮詢小組研討會，以檢驗假設並確定證據需求的優先順序。

簡明扼要地總結了臨床創新、程序趨勢和商業性需求，從而為相關人員。

目前，關節疼痛注射療法正處於臨床創新、操作精準性和商業性可行性三者交會的十字路口。生物製藥生產技術的進步、更有效的透明質酸化學成分以及影像引導技術的普及，正在重新定義人們對安全性和有效性的預期；與此同時，保險公司和採購負責人的嚴格審查也使得對治療效果的嚴謹證據提出了更高的要求。此外，關稅等政策措施也凸顯了供應鏈策略和在地化生產決策在確保藥物可及性和永續定價方面的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：關節疼痛治療注射藥物市場－依分子類型分類

  • 皮質類固醇
    • Betamethasone
    • Methylprednisolone
    • 曲安奈德
  • 玻尿酸
    • 交聯型
    • 線性類型
  • 富血小板血漿
    • 白血球去除
    • 白血球計數豐富

第9章：注射用關節疼痛藥物市場：依適應症分類

  • 痛風
    • 急性治療
    • 慢性期管理
  • 骨關節炎
    • 髖關節
    • 膝蓋
    • 肩膀
  • 類風濕性關節炎
    • 大關節
    • 小關節

第10章：關節疼痛治療注射藥物市場：依給藥途徑分類

  • 關節內
    • 基於解剖標誌
    • 超音波引導
  • 肌肉內部
    • 深層組織
    • 表
  • 關節週長
    • 基於解剖標誌
    • 超音波引導

第11章：依患者年齡層分類的關節疼痛注射藥物市場

  • 青年
  • 成人
  • 老年人
  • 兒童

第12章：關節疼痛治療注射藥物市場：依最終使用者分類

  • 門診手術中心
  • 醫院
  • 整形外科診所
  • 風濕病診所

第13章：關節疼痛治療注射藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：關節疼痛治療注射劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 注射用關節疼痛藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國關節疼痛治療注射市場

第17章：中國關節疼痛注射劑市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Anika Therapeutics, Inc.
  • Bioventus Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • Ferring Pharmaceuticals A/S
  • Fidia Farmaceutici SpA
  • Flexion Therapeutics, Inc.
  • Hysingla
  • Johnson & Johnson
  • Kane Biotech, Inc.
  • Lifecore Biomedical, LLC
  • OrthogenRx, Inc.
  • Pacira BioSciences, Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Seikagaku Corporation
  • Stryker Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-43470FC6083D

The Joint Pain Injections Market was valued at USD 5.57 billion in 2025 and is projected to grow to USD 6.16 billion in 2026, with a CAGR of 11.38%, reaching USD 11.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.57 billion
Estimated Year [2026] USD 6.16 billion
Forecast Year [2032] USD 11.85 billion
CAGR (%) 11.38%

Comprehensive introduction to the clinical, technological, and commercial drivers reshaping the global joint pain injection ecosystem for decision-makers

Joint pain injections occupy a central role in contemporary orthopedics, rheumatology, and sports medicine as clinicians seek effective, targeted interventions that offer symptom relief with minimal downtime. Over the past decade, clinicians have balanced established corticosteroid injections with an expanding repertoire of biologic and viscosupplementation options, while procedural technique and imaging guidance have become increasingly pivotal to outcomes. As a result, the clinical conversation has shifted from single-treatment paradigms toward integrated pathways that prioritize safety, reproducibility, and patient-reported functional gains.

Clinicians and health systems now operate within a context defined by tighter reimbursement pressures, growing patient demand for needle-sparing and regenerative approaches, and heightened attention to procedure-site safety and documentation. In addition, outpatient settings such as ambulatory surgical centers and specialty clinics are accelerating adoption of minimally invasive interventions, which in turn shapes procurement strategies and training priorities. Taken together, these forces are prompting manufacturers, device makers, and clinical service providers to align product innovation, physician education, and value demonstration to sustain adoption and to address payer expectations.

Detailed exploration of transformative technological, clinical, and policy shifts that are accelerating adoption and changing standards of care in joint pain injection therapies

Clinical practice and commercial landscapes for joint pain injections are undergoing transformative shifts driven by converging advances in biologics, imaging, and reimbursement frameworks. First, the increasing clinical interest in regenerative approaches has elevated platelet-rich plasma and related autologous therapies from niche options to mainstream investigational choices, prompting manufacturers to refine processing kits and quality controls. Meanwhile, improvements in hyaluronic acid formulations and the continued use of corticosteroids maintain their therapeutic relevance, but with more nuanced positioning based on patient profile and joint-specific outcomes.

Concurrently, imaging-enabled delivery, most notably ultrasound-guided injections, has moved from specialized centers into routine practice, improving targeting accuracy and reinforcing claims of superior clinical outcomes and reduced complication rates. Health systems and payers are responding by emphasizing procedure documentation and real-world outcomes, which drives greater investment in data capture and quality registries. Finally, the sector's commercial logic is shifting as supply chain resilience, localized manufacturing, and strategic partnerships become critical to managing cost pressures and regulatory complexity. As stakeholders adapt, those who integrate clinical evidence generation with clinician training and robust post-market surveillance will realize asymmetric advantages in adoption and trust.

Rigorous analysis of how U.S. tariff measures enacted in 2025 reshaped sourcing, pricing dynamics, and supply chain strategies for joint pain injection therapies

The cumulative effects of tariff changes implemented in the United States in 2025 have reverberated across procurement, pricing, and supply chain decision-making for joint pain injection products and their components. Increased duties on certain imported medical inputs elevated landed costs for disposable kits, hyaluronic acid starting materials, and certain device components, which in turn prompted immediate supplier negotiations and a reevaluation of sourcing strategies. In response, multinational manufacturers accelerated efforts to localize production, shift higher-value assembly onshore, or requalify alternative suppliers in tariff-exempt jurisdictions to mitigate margin compression.

As a consequence of these shifts, procurement cycles lengthened while contract renegotiations and cost-pass-through discussions took place between suppliers, distributors, and provider organizations. Payers and hospital procurement teams increasingly scrutinized unit economics and total cost of care, reinforcing the need for manufacturers to demonstrate durable clinical benefit and cost-offsets. At the same time, smaller innovators and contract manufacturers faced heightened barriers to entering the U.S. market unless they adapted pricing models or established domestic partnerships. Looking forward, regulatory compliance, customs classification clarity, and bilateral supplier agreements have become critical tactical levers for stakeholders seeking to preserve access while managing commercial viability.

In-depth segmentation insights that connect molecule types, clinical indications, routes of administration, care settings, and patient age cohorts to practical adoption strategies

When evaluated by molecule type, the landscape distinguishes between established corticosteroids, various hyaluronic acid formulations, and platelet-rich plasma approaches, each presenting distinct clinical and commercial implications. The corticosteroid segment includes well-characterized agents such as Betamethasone, Methylprednisolone Acetate, and Triamcinolone Acetonide, with differences in potency, depot behavior, and duration of symptom relief influencing clinician selection. Hyaluronic acid offerings diverge across cross-linked and linear formulations, where cross-linked variants often aim to extend residence time within the joint and target longer symptom control, while linear formulations emphasize simplicity, lower viscosity, and potentially better immediate joint compliance. Platelet-rich plasma is differentiated into leukocyte-poor and leukocyte-rich preparations, and these biologic distinctions affect inflammatory profiles, regulatory oversight, and procedural handling requirements.

Based on indication, treatment pathways vary across gout, osteoarthritis, and rheumatoid arthritis. In gout the focus separates acute management from chronic management, which drives differences in medication choice and urgency of intervention. Osteoarthritis practice differentiates by joint site-hip, knee, and shoulder-with knee injections historically representing the largest procedural volume while hip and shoulder approaches demand higher imaging precision. Rheumatoid arthritis requires a different framing, as care pathways for large joints and small joints prioritize systemic disease control alongside local symptom relief.

Based on route of administration, clinicians select between intra-articular, intramuscular, and peri-articular approaches, with intra-articular procedures further distinguished by landmark-based or ultrasound-guided techniques. Intramuscular injections split into deep tissue and superficial approaches, each with distinct needle selection and recovery considerations, while peri-articular delivery also differentiates by landmark-based versus ultrasound-guided methods that affect accuracy and complication risk. Based on end user, the services are delivered across ambulatory surgical centers, hospitals, orthopedic clinics, and rheumatology clinics, with each setting imposing different credentials, billing pathways, and throughput constraints. Based on patient age group, clinical decision-making must account for adolescents, adults, elderly patients, and pediatrics, where comorbidities, growth considerations, and long-term safety profiles shape both product selection and procedural planning.

Collectively, these multi-dimensional segmentation lenses reveal that clinical adoption and commercial success hinge on aligning formulation properties, delivery technique, and site-of-care logistics with payer expectations and patient-centric outcomes. As a result, product teams and clinician educators must tailor evidence generation and training to specific molecule-route-indication permutations to accelerate acceptance and optimize outcomes.

Key regional perspectives highlighting how reimbursement, regulation, clinical practice patterns, and manufacturing capacity vary across major global regions

Regional dynamics continue to drive differentiated strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific, with each region presenting unique regulatory environments, reimbursement frameworks, and clinical practice patterns. In the Americas, a concentrated emphasis on outpatient procedural growth, ambulatory surgical center capacity, and payer scrutiny shapes purchasing and clinical adoption, prompting manufacturers to prioritize evidence demonstrating comparative effectiveness and procedural efficiency. Transitioning from hospital-centric care to decentralized settings has also spurred investment in training programs that help standardize ultrasound-guided techniques across diverse provider networks.

Across Europe, Middle East & Africa, regulatory harmonization and national reimbursement policies create a patchwork of access profiles that favor products with robust clinical data and clear cost-offset narratives. In many jurisdictions, clinicians emphasize long-term safety and quality-of-life metrics, and national procurement bodies often drive volume purchasing decisions that favor standardized, cost-effective options. Meanwhile, in the Asia-Pacific region, rapid adoption of innovative delivery techniques, a growing base of procedure-trained clinicians, and expanding domestic manufacturing capacity are reshaping competitive dynamics. Price sensitivity coexists with a strong interest in regenerative and minimally invasive approaches, encouraging hybrid strategies that combine localized production with targeted clinical evidence generation. Understanding these regional contours enables manufacturers and service providers to tailor regulatory strategies, distribution partnerships, and evidence programs to region-specific priorities and payer architectures.

Strategic company-level insights revealing how partnerships, portfolio integration, and evidence generation shape competitive advantages in joint pain injection offerings

Competitive dynamics among companies operating in the joint pain injection space reflect strategic moves to integrate product portfolios, expand service offerings, and secure distribution channels. Established pharmaceutical manufacturers continue to optimize corticosteroid and hyaluronic acid lines while selectively investing in specialty biologics and device-enabled delivery solutions. At the same time, device and diagnostic firms are partnering with biologic innovators to offer bundled solutions that combine injectables with guidance systems, procedural kits, and clinician training-strengthening the value proposition for providers and payers.

Newer entrants and mid-sized firms often differentiate through processing innovations for autologous therapies, streamlined disposables, or cost-effective kit designs that address site-of-care constraints. Across the competitive set, a consistent strategic theme is the pursuit of integrated evidence-generation programs that couple randomized clinical studies with real-world registries and patient-reported outcome capture. Additionally, companies are reallocating commercial investments toward outpatient channels, direct clinician education, and contracting models that align pricing with demonstrated outcomes. As a result, partnerships, licensing agreements, and selective vertical integration are emerging as preferred pathways to scale while managing regulatory complexity and capital intensity.

Actionable recommendations for manufacturers, clinicians, and payers to build supply resilience, validate clinical value, and accelerate adoption across care settings

Industry leaders should prioritize a set of pragmatic actions to translate insight into resilient growth and clinical impact. First, invest in supply chain resilience by diversifying suppliers, qualifying domestic manufacturing partners where feasible, and maintaining clear customs and classification strategies; doing so reduces exposure to tariff shocks and short-term disruptions. Second, commit to clinician training programs that emphasize ultrasound-guided delivery and standardized protocols, because procedural accuracy directly influences perceived effectiveness and payer acceptance.

Third, align product development with indication-specific evidence plans that address the clinical questions most relevant to payers and high-volume providers; this includes targeted outcomes for hip, knee, and shoulder interventions, and comparative analyses relative to systemic therapies in inflammatory conditions. Fourth, build modular commercial models that accommodate ambulatory surgical centers, hospitals, and specialty clinics, enabling flexible contracting and tiered pricing that reflect differing site-of-care economics. Fifth, pursue partnerships that integrate delivery devices, digital outcome capture, and post-market registries to substantiate value. Finally, adopt a patient-centric communications strategy that emphasizes safety, recovery timelines, and functional outcomes to improve uptake and reduce friction at the point of care. Collectively, these steps create an aligned playbook that balances short-term resilience with long-term clinical credibility.

Transparent description of the mixed-method research approach combining clinician interviews, supplier intelligence, regulatory review, and expert validation to produce robust insights

This analysis relied on a multi-method research approach that combined primary qualitative engagement with validated secondary intelligence to ensure balanced and auditable insights. The primary research included in-depth interviews with practicing orthopedic surgeons, rheumatologists, interventional radiologists, and procedure nurses, as well as structured discussions with procurement leads and regulatory experts across major regions. These interviews were supplemented by advisory-panel workshops that stress-tested hypotheses and prioritized evidence needs.

Secondary research incorporated review of peer-reviewed clinical literature, regulatory filings, product labels, and device guidance documents to map clinical indications, contraindications, and procedure protocols. The methodology also leveraged supplier and distributor interviews to assess supply chain pathways, lead times, and contractual norms. Data synthesis applied rigorous qualitative coding and triangulation to reconcile divergent viewpoints, and findings were validated through an expert review process to ensure credibility. Where appropriate, real-world practice patterns were inferred from clinical guidelines and procedural training curricula to contextualize adoption dynamics. Throughout, the research team adhered to transparent data provenance, strict conflict-of-interest checks, and iterative validation with clinical advisors to maintain robustness and relevance.

Concise conclusion drawing together clinical innovation, procedural trends, and commercial imperatives to define strategic priorities for stakeholders

The joint pain injection landscape is at an inflection point where clinical innovation, procedural precision, and commercial pragmatism intersect. Advances in biologic processing, more effective hyaluronic acid chemistries, and wider adoption of imaging-guided techniques are redefining expectations around safety and efficacy, while payer and procurement scrutiny drive the need for rigorous outcome evidence. At the same time, policy actions such as tariffs have emphasized the importance of supply chain strategy and local manufacturing decisions in preserving access and sustainable pricing.

For stakeholders across the value chain, the imperative is clear: align product development with indication- and route-specific evidence, invest in clinician training to secure consistent delivery quality, and adopt flexible commercial models that reflect diverse site-of-care economics. By doing so, manufacturers and providers can both improve patient outcomes and create defensible positions in a market characterized by rapid clinical evolution and intensified operational scrutiny. The next phase will reward organizations that marry clinical credibility with operational agility.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Joint Pain Injections Market, by Molecule Type

  • 8.1. Corticosteroids
    • 8.1.1. Betamethasone
    • 8.1.2. Methylprednisolone Acetate
    • 8.1.3. Triamcinolone Acetonide
  • 8.2. Hyaluronic Acid
    • 8.2.1. Cross-Linked
    • 8.2.2. Linear
  • 8.3. Platelet-Rich Plasma
    • 8.3.1. Leukocyte-Poor
    • 8.3.2. Leukocyte-Rich

9. Joint Pain Injections Market, by Indication

  • 9.1. Gout
    • 9.1.1. Acute Management
    • 9.1.2. Chronic Management
  • 9.2. Osteoarthritis
    • 9.2.1. Hip
    • 9.2.2. Knee
    • 9.2.3. Shoulder
  • 9.3. Rheumatoid Arthritis
    • 9.3.1. Large Joints
    • 9.3.2. Small Joints

10. Joint Pain Injections Market, by Route Of Administration

  • 10.1. Intra-Articular
    • 10.1.1. Landmark-Based
    • 10.1.2. Ultrasound-Guided
  • 10.2. Intramuscular
    • 10.2.1. Deep Tissue
    • 10.2.2. Superficial
  • 10.3. Peri-Articular
    • 10.3.1. Landmark-Based
    • 10.3.2. Ultrasound-Guided

11. Joint Pain Injections Market, by Patient Age Group

  • 11.1. Adolescents
  • 11.2. Adults
  • 11.3. Elderly
  • 11.4. Pediatrics

12. Joint Pain Injections Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
  • 12.3. Orthopedic Clinics
  • 12.4. Rheumatology Clinics

13. Joint Pain Injections Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Joint Pain Injections Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Joint Pain Injections Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Joint Pain Injections Market

17. China Joint Pain Injections Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Anika Therapeutics, Inc.
  • 18.6. Bioventus Inc.
  • 18.7. Chugai Pharmaceutical Co., Ltd.
  • 18.8. Eli Lilly and Company
  • 18.9. Ferring Pharmaceuticals A/S
  • 18.10. Fidia Farmaceutici S.p.A.
  • 18.11. Flexion Therapeutics, Inc.
  • 18.12. Hysingla
  • 18.13. Johnson & Johnson
  • 18.14. Kane Biotech, Inc.
  • 18.15. Lifecore Biomedical, LLC
  • 18.16. OrthogenRx, Inc.
  • 18.17. Pacira BioSciences, Inc.
  • 18.18. Pfizer Inc.
  • 18.19. Regeneron Pharmaceuticals, Inc.
  • 18.20. Sanofi S.A.
  • 18.21. Seikagaku Corporation
  • 18.22. Stryker Corporation
  • 18.23. Teva Pharmaceutical Industries Ltd.
  • 18.24. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL JOINT PAIN INJECTIONS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL JOINT PAIN INJECTIONS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY BETAMETHASONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY BETAMETHASONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY BETAMETHASONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE ACETATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE ACETATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE ACETATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY TRIAMCINOLONE ACETONIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY TRIAMCINOLONE ACETONIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY TRIAMCINOLONE ACETONIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CROSS-LINKED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CROSS-LINKED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CROSS-LINKED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LINEAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LINEAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LINEAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-POOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-POOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-POOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-RICH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-RICH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-RICH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ACUTE MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ACUTE MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ACUTE MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CHRONIC MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CHRONIC MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CHRONIC MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HIP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HIP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HIP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY KNEE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY KNEE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY KNEE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SHOULDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SHOULDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SHOULDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY DEEP TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY DEEP TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY DEEP TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SUPERFICIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SUPERFICIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SUPERFICIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ELDERLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ELDERLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ELDERLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ORTHOPEDIC CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ORTHOPEDIC CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ORTHOPEDIC CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 267. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 268. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2032 (USD MILLION)
  • TABLE 269. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 270. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2032 (USD MILLION)
  • TABLE 271. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 272. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 273. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 275. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 276. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 277. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 278. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 310. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 312. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 313. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2032 (USD MILLION)
  • TABLE 314. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 315. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2032 (USD MILLION)
  • TABLE 316. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 317. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 318. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 319. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 320. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 321. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 322. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 323. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 324. NATO JOINT